We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.05%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.32B
AUM Growth
+$456M
(+7.8%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
17.62%
Holding
844
New
72
Increased
349
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$37.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$29.3M |
| 3 |
Biogen
BIIB
|
+$27.4M |
| 4 |
Home Depot
HD
|
+$22.7M |
| 5 |
Cisco
CSCO
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$23.6M |
| 2 |
TJX Companies
TJX
|
+$19.3M |
| 3 |
FedEx
FDX
|
+$16.4M |
| 4 |
Intuit
INTU
|
+$14.7M |
| 5 |
Corning
GLW
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Technology | 17.19% |
| 3 | Financials | 12.85% |
| 4 | Consumer Discretionary | 10.2% |
| 5 | Communication Services | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ELGX
551
DELISTED
Endologix Inc
ELGX
| $1.25M | 0.02% |
22,000
| – | – |
|
552
Idexx Laboratories
IDXX
$42.9B
| $1.23M | 0.02% |
+5,635
| New | +$1.16M |
|
|
TFCF
553
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
| $1.23M | 0.02% |
24,895
-6,852
| -22% | -$268K |
|
554
HF Sinclair
DINO
$15.9B
| $1.22M | 0.02% |
17,804
-4,644
| -21% | -$309K |
|
555
Thomson Reuters
TRI
$39.4B
| $1.22M | 0.02% |
26,024
+2,334
| +10% | +$107K |
|
556
Akamai
AKAM
$16.8B
| $1.19M | 0.02% |
16,296
| – | – |
|
557
Eastman Chemical
EMN
$7.8B
| $1.19M | 0.02% |
11,929
-2,841
| -19% | -$300K |
|
558
Lamb Weston
LW
$6.82B
| $1.18M | 0.02% |
17,201
| – | – |
|
|
ESPR
559
DELISTED
Esperion Therapeutics
ESPR
| $1.18M | 0.02% |
30,000
| – | – |
|
560
Targa Resources
TRGP
$60.4B
| $1.16M | 0.02% |
23,506
+768
| +3% | +$36.5K |
|
|
AMTD
561
DELISTED
TD Ameritrade Holding Corp
AMTD
| $1.15M | 0.02% |
20,902
-1,957
| -9% | -$117K |
|
562
Warner Bros
WBD
$64.6B
| $1.14M | 0.02% |
+41,565
| New | +$991K |
|
563
Healthpeak Properties
DOC
$15.4B
| $1.14M | 0.02% |
44,130
| – | – |
|
564
Mattel
MAT
$4.17B
| $1.14M | 0.02% |
69,124
| – | – |
|
|
XENT
565
DELISTED
Intersect ENT, Inc
XENT
| $1.12M | 0.02% |
30,000
| – | – |
|
566
Brown-Forman Class B
BF.B
$12B
| $1.11M | 0.02% |
22,684
-2,199
| -9% | -$120K |
|
567
Imperial Oil
IMO
$62.1B
| $1.11M | 0.02% |
33,463
-3,265
| -9% | -$102K |
|
568
Ardelyx
ARDX
$1.24B
| $1.11M | 0.02% |
300,000
| – | – |
|
569
Celanese
CE
$5.09B
| $1.11M | 0.02% |
9,960
-1,088
| -10% | -$120K |
|
|
AKAO
570
DELISTED
Achaogen Inc
AKAO
| $1.1M | 0.02% |
127,555
-95,000
| -43% | -$1.16M |
|
|
ABMD
571
DELISTED
Abiomed Inc
ABMD
| $1.1M | 0.02% |
+2,693
| New | +$976K |
|
|
XL
572
DELISTED
XL Group Ltd.
XL
| $1.1M | 0.02% |
19,582
| – | – |
|
573
Domino's
DPZ
$11B
| $1.08M | 0.02% |
3,818
+813
| +27% | +$206K |
|
574
AGNC Investment
AGNC
$12.3B
| $1.08M | 0.02% |
57,881
+5,224
| +10% | +$98.7K |
|
575
Hershey
HSY
$35.4B
| $1.07M | 0.02% |
11,536
+1,856
| +19% | +$173K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2018 Portfolio in Review
As of Q2 2018, Candriam SCA held 844 positions worth $6.32B, up 7.8% from $5.86B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA deployed $224M of net new capital in Q2 2018, opening 72 new positions and adding to 349 existing holdings. Its largest new stake was Broadcom: 1,532,450 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $23.6M trimmed.
- Candriam SCA's largest Q2 2018 buy was Broadcom: 1,532,450 shares worth $37.2M.
- Candriam SCA added most to Bristol-Myers Squibb in Q2 2018, an estimated $29.3M increase.
- Candriam SCA's biggest Q2 2018 reduction was JPMorgan Chase, cutting an estimated $23.6M.
- Candriam SCA fully exited Monsanto Co in Q2 2018, selling an estimated $11.5M.
- Candriam SCA's ten largest holdings make up 18% of its $6.32B portfolio in Q2 2018.
- Candriam SCA opened 72 new positions and closed 60 in Q2 2018.
- Candriam SCA's portfolio value rose 7.8% quarter-over-quarter to $6.32B.
Based on Candriam SCA's 13F filing for Q2 2018, filed 14 Aug 2018.